Verrica Pharmaceuticals Inc. (VRCA)Healthcare | Biotechnology | West Chester, United States | NasdaqCM
6.32 USD
+0.11
(1.771%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.32 Short-term: ★★★★★ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:14 a.m. EDT
Verrica Pharmaceuticals (VRCA) is currently in a high-conviction short-term trade driven by a catalyst ritual of regulatory approvals, strategic financing, and near-universal analyst upgrades, pushing the stock toward a target price of $16.50 (97% upside). However, the stock fails all fundamental long-term tests; it has a shrinking balance sheet, negative operating cash flow, no revenue growth sustainability, and zero dividend yield, classifying it as a speculative gamble rather than an investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.292929 |
| MSTL | 0.306437 |
| AutoARIMA | 0.703503 |
| AutoTheta | 0.716702 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.60 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.740 |
| Excess Kurtosis | -0.53 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.592 |
| Revenue per Share | 3.34 |
| Market Cap | 108,569,928 |
| Forward P/E | -3.71 |
| Beta | 1.43 |
| Profit Margins | -50.27% |
| Website | https://www.verrica.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.3591398 |
| Address1 | 44 West Gay Street |
| Address2 | Suite 400 |
| All Time High | 232.9 |
| All Time Low | 3.28 |
| Ask | 6.44 |
| Ask Size | 1 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 95,730 |
| Average Daily Volume3 Month | 126,416 |
| Average Volume | 126,416 |
| Average Volume10Days | 95,730 |
| Beta | 1.428 |
| Bid | 6.15 |
| Bid Size | 1 |
| Book Value | 1.44 |
| City | West Chester |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.32 |
| Current Ratio | 2.588 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.6 |
| Day Low | 6.21 |
| Debt To Equity | 6.592 |
| Display Name | Verrica Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,232,200 |
| Earnings Call Timestamp Start | 1,773,232,200 |
| Earnings Timestamp | 1,773,232,200 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -11,454,000 |
| Ebitda Margins | -0.32195 |
| Enterprise To Ebitda | -6.989 |
| Enterprise To Revenue | 2.25 |
| Enterprise Value | 80,053,928 |
| Eps Current Year | -2.075 |
| Eps Forward | -1.705 |
| Eps Trailing Twelve Months | -1.68 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.656 |
| Fifty Day Average Change | 0.66400003 |
| Fifty Day Average Change Percent | 0.11739746 |
| Fifty Two Week Change Percent | 35.91398 |
| Fifty Two Week High | 9.821 |
| Fifty Two Week High Change | -3.501 |
| Fifty Two Week High Change Percent | -0.356481 |
| Fifty Two Week Low | 3.28 |
| Fifty Two Week Low Change | 3.0400002 |
| Fifty Two Week Low Change Percent | 0.92682934 |
| Fifty Two Week Range | 3.28 - 9.821 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,069,400,000 |
| Float Shares | 6,777,375 |
| Forward Eps | -1.705 |
| Forward P E | -3.706745 |
| Free Cashflow | -15,459,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.65438 |
| Gross Profits | 23,281,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.48249 |
| Held Percent Institutions | 0.30254 |
| Implied Shares Outstanding | 17,178,786 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,401,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. |
| Long Name | Verrica Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 108,569,928 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_319720251 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -17,886,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 108,569,927 |
| Number Of Analyst Opinions | 4 |
| Open | 6.32 |
| Operating Cashflow | -17,627,000 |
| Operating Margins | -1.3641 |
| Payout Ratio | 0.0 |
| Phone | 484 453 3300 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.32 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 6.21 |
| Price Eps Current Year | -3.045783 |
| Price Hint | 2 |
| Price To Book | 4.388889 |
| Price To Sales Trailing12 Months | 3.0516887 |
| Profit Margins | -0.50273997 |
| Quick Ratio | 2.162 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.4 |
| Region | US |
| Regular Market Change | 0.11 |
| Regular Market Change Percent | 1.77134 |
| Regular Market Day High | 6.6 |
| Regular Market Day Low | 6.21 |
| Regular Market Day Range | 6.21 - 6.6 |
| Regular Market Open | 6.32 |
| Regular Market Previous Close | 6.21 |
| Regular Market Price | 6.32 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 91,824 |
| Return On Assets | -0.14737001 |
| Return On Equity | -2.40355 |
| Revenue Growth | 13.802 |
| Revenue Per Share | 3.34 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,178,786 |
| Shares Percent Shares Out | 0.029000001 |
| Shares Short | 497,753 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 405,005 |
| Short Name | Verrica Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0381 |
| Short Ratio | 3.59 |
| Source Interval | 15 |
| State | PA |
| Symbol | VRCA |
| Target High Price | 20.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 16.5 |
| Target Median Price | 18.0 |
| Total Cash | 30,147,000 |
| Total Cash Per Share | 1.755 |
| Total Debt | 1,631,000 |
| Total Revenue | 35,577,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.97235 |
| Two Hundred Day Average Change | 0.34765005 |
| Two Hundred Day Average Change Percent | 0.058209926 |
| Type Disp | Equity |
| Volume | 91,824 |
| Website | https://www.verrica.com |
| Zip | 19,380 |